Clinical Trial: GEPAKTIV VS UDCA AND ADEMETIONINE IN MAFLD WITH HEPATOMEGALY

U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07068191) titled 'GEPAKTIV VS UDCA AND ADEMETIONINE IN MAFLD WITH HEPATOMEGALY' on July 07.

Brief Summary: This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).

Key points:

* Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days

* Doctors will monitor liver health through blood tests and ultrasound scans

* The study will check if Gepaktiv helps improve liver function as effectively as standard treatments.

Main measurements:

* Changes in liver enzyme levels (ALT, AST)

* Re...